EMERSON PERIN to Myocardium
This is a "connection" page, showing publications EMERSON PERIN has written about Myocardium.
Connection Strength
1.323
-
From state-of-the-art cell therapy to endogenous cardiac repair. EuroIntervention. 2017 Aug 25; 13(6):760-772.
Score: 0.385
-
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):169-177.
Score: 0.361
-
Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. PLoS One. 2011; 6(9):e22949.
Score: 0.254
-
CD34+ autologous human stem cells in treating refractory angina. Circ Res. 2011 Aug 05; 109(4):351-2.
Score: 0.063
-
A dosing study of bone marrow mononuclear cells for transendocardial injection in a pig model of chronic ischemic heart disease. Tex Heart Inst J. 2011; 38(3):219-24.
Score: 0.061
-
Histopathological study of healing after allogenic mesenchymal stem cell delivery in myocardial infarction in dogs. J Histochem Cytochem. 2009 Feb; 57(2):167-76.
Score: 0.052
-
Transendocardial autologous bone marrow mononuclear cell injection in ischemic heart failure: postmortem anatomicopathologic and immunohistochemical findings. Circulation. 2005 Jul 26; 112(4):521-6.
Score: 0.042
-
Transendocardial injection of autologous mononuclear bone marrow cells in end-stage ischemic heart failure patients: one-year follow-up. Int J Cardiol. 2004 Jun; 95 Suppl 1:S45-6.
Score: 0.038
-
Cardiac sarcoidosis. An unusual form of acute congestive cardiomyopathy. Tex Heart Inst J. 1995; 22(3):265-7.
Score: 0.020
-
Do we have a future with transcatheter adventitial delivery of stem cells? Int J Cardiol. 2013 May 10; 165(2):217-21.
Score: 0.017
-
Synthesis and evaluation of an anti-MLC1 ? anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium. Bioconjug Chem. 2011 Aug 17; 22(8):1706-14.
Score: 0.016
-
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010; 37(4):412-20.
Score: 0.014